Human ACE and bradykinin B2 receptors form a complex at the plasma membrane

被引:35
作者
Chen, Zhenlong
Deddish, Peter A.
Minshall, Richard D.
Becker, Robert P.
Erdos, Ervin G.
Tan, Fulong
机构
[1] Univ Illinois, Coll Med, Dept Pharmacol, Lab Peptide Res, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA
[3] Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL 60612 USA
关键词
oligomer; FRET; converting enzyme; peptide receptors; kinins;
D O I
10.1096/fj.06-6113com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To investigate how angiotensin I-converting enzyme ( ACE) inhibitors enhance the actions of bradykinin (BK) on B-2 receptors independent of blocking BK inactivation, we expressed human somatic ACE and B-2 receptors in CHO cells. Bradykinin and its ACE-resistant analog were the receptor agonists. B-2 fused with green fluorescent protein (GFP) and ACE were coprecipitated with antisera to GFP or ACE shown in Western blots. Immunohistochemistry of fixed cells localized ACE by red color and B-2-GFP by green. Yellow on plasma membranes of coexpressing cells also indicated enzyme-receptor complex formation. Using ACE-fused cyan fluorescent protein donor and B-2-fused yellow fluorescent protein (YFP) acceptor, we registered fluorescence resonance energy transfer (FRET) by the enhanced fluorescence of donor on acceptor photobleaching, establishing close (within 10 nm) positions of B-2 receptors and ACE. Bradykinin stimulation cointernalized ACE and B-2 receptors. We expressed ACE fused to N terminus of B-2 receptors, anchoring only receptors to plasma membranes. Here, in contrast to cells, where both ACE and B-2 receptors are separately anchored, ACE inhibitors neither enhance activation of chimeric B-2 nor resensitize desensitized B-2 receptors. Heterodimer formation between ACE and B-2 receptors can be a mechanism for ACE inhibitors to augment kinin activity at cellular level.
引用
收藏
页码:2261 / 2270
页数:10
相关论文
共 51 条
[31]   Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9α [J].
Mueller, S ;
Gothe, R ;
Siems, WD ;
Vietinghoff, G ;
Paegelow, I ;
Reissmann, S .
PEPTIDES, 2005, 26 (07) :1235-1247
[32]  
PAGE IH, 1998, HYPERTENSION RES MEM, P1
[33]   Angiotensin-converting enzyme inhibitors - A new mechanism of action [J].
Peng, HM ;
Carretero, OA ;
Vuljaj, N ;
Liao, TD ;
Motivala, A ;
Peterson, EL ;
Rhaleb, NE .
CIRCULATION, 2005, 112 (16) :2436-2445
[34]  
PFEFFER M, 2001, ANGIOTENSIN CONVERTI, P219
[35]   Heterodimerization of substance P and μ-opioid receptors regulates receptor trafficking and resensitization [J].
Pfeiffer, M ;
Kirscht, S ;
Stumm, R ;
Koch, T ;
Wu, DF ;
Laugsch, M ;
Schröder, H ;
Höllt, V ;
Schulz, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (51) :51630-51637
[36]  
RUBIN B, 1978, J PHARMACOL EXP THER, V204, P271
[37]   Homodimerization of the β2-adrenergic receptor as a prerequisite for cell surface targeting [J].
Salahpour, A ;
Angers, S ;
Mercier, JF ;
Lagacé, M ;
Marullo, S ;
Bouvier, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) :33390-33397
[38]  
SIEGEL RM, 2000, SCI STKE, pPL1
[39]  
Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10
[40]   Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic. study [J].
Solomon, SD ;
Skali, H ;
Bourgoun, M ;
Fang, J ;
Ghali, JK ;
Martelet, M ;
Wojciechowski, D ;
Ansmite, B ;
Skards, J ;
Laks, T ;
Henry, D ;
Packer, M ;
Pfeffer, MA .
AMERICAN HEART JOURNAL, 2005, 150 (02) :257-262